The Irish Medicines Board (IMB) has recently published important safety information communication on the difference in risk of thromboembolism between products, the importance of individual risk factors and to remain vigilant for signs and symptoms of combined hormonal contraceptives (CHCs).

This information will be of interest to Registered Nurse Prescribers, nurses and midwives working in the area of family planning.   Click here for more information.